Study protocol for the Melbourne Infant Study: BCG for Allergy and Infection Reduction (MIS BAIR), a randomised controlled trial to determine the non-specific effects of neonatal BCG vaccination in a low-mortality setting

Nicole L Messina, Kaya Gardiner, Susan Donath, Katie Flanagan, Anne-Louise Ponsonby, Frank Shann, Roy Robins-Browne, Bridget Freyne, Veronica Abruzzo, Clare Morison, Lianne Cox, Susie Germano, Christel Zufferey, Petra Zimmermann, Katie J Allen, Peter Vuillermin, Mike South, Dan Casalaz, Nigel Curtis, Nicole L Messina, Kaya Gardiner, Susan Donath, Katie Flanagan, Anne-Louise Ponsonby, Frank Shann, Roy Robins-Browne, Bridget Freyne, Veronica Abruzzo, Clare Morison, Lianne Cox, Susie Germano, Christel Zufferey, Petra Zimmermann, Katie J Allen, Peter Vuillermin, Mike South, Dan Casalaz, Nigel Curtis

Abstract

Introduction: BCG vaccination reduces all-cause infant mortality in high-mortality settings by more than can be attributed to protection against tuberculosis. This is proposed to result from non-specific protection against non-vaccine targeted ('off-target') infections. There is also evidence that BCG protects against allergic diseases.

Methods and analysis: The Melbourne Infant Study: BCG for Allergy and Infection Reduction is a phase III multicentre, single-blinded, randomised controlled trial. A total of 1438 healthy neonates will be randomised to receive either BCG vaccination or no BCG vaccination in the first 10 days of life. Measures of allergy, eczema, infection and asthma will be obtained from parent-completed questionnaires 3 monthly in the first year and 6 monthly from 1 to 5 years of age, and clinical assessments at 1 and 5 years of age. Biological samples will also be collected for future immunological studies.

Analysis primary outcome: The proportion of participants with measures of allergy and infection (atopic sensitisation, eczema, lower respiratory tract infection) at 1 and 5 years of age, and asthma at 5 years of age.

Secondary outcomes: (1) the proportion of participants with additional measures of allergy, eczema, asthma and infections; (2) medication use for eczema and asthma; (3) the severity and age of onset of eczema and asthma; (4) the number of episodes of infection; (5) hospitalisations for infections and (6) laboratory measures of immune responses.

Ethics and dissemination: This trial has ethical and governance approval from Mercy Health Human Research Ethics Committee (HREC, No. R12-28) and Royal Children's Hospital HREC (No. 33025) with additional governance approval from Barwon Health and St John of God, Geelong, Victoria. Results of this trial will be published in peer-reviewed journals and presented at scientific conferences.

Trial registration number: NCT01906853.

Keywords: allergy; asthma; eczema; immunology; immunsation; infectious diseases; paediatric.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. World Health Organization Immunization coverage estimates by who region: BCG, 2018.
    1. Higgins JPT, Soares-Weiser K, López-López JA, et al. . Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ 2016;355 10.1136/bmj.i5170
    1. Pollard AJ, Finn A, Curtis N. Non-Specific effects of vaccines: plausible and potentially important, but implications uncertain. Arch Dis Child 2017;102:1077–81. 10.1136/archdischild-2015-310282
    1. Biering-Sorensen S, Aaby P, Lund N, et al. . Early BCG-Denmark and neonatal mortality among infants weighing. Clin Infect Dis 2017;65:1183–90.
    1. Aaby P, Roth A, Ravn H, et al. . Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis 2011;204:245–52. 10.1093/infdis/jir240
    1. Freyne B, Curtis N. Does neonatal BCG vaccination prevent allergic disease in later life? Arch Dis Child 2014;99:182–4. 10.1136/archdischild-2013-305655
    1. Arnoldussen DL, Linehan M, Sheikh A. BCG vaccination and allergy: a systematic review and meta-analysis. J Allergy Clin Immunol 2011;127:246–53. 10.1016/j.jaci.2010.07.039
    1. Rousseau M-C, Parent M-E, St-Pierre Y. Potential health effects from non-specific stimulation of the immune function in early age: the example of BCG vaccination. Pediatr Allergy Immunol 2008;19:438–48. 10.1111/j.1399-3038.2007.00669.x
    1. El-Zein M, Parent ME, Benedetti A, et al. . Does BCG vaccination protect against the development of childhood asthma? A systematic review and meta-analysis of epidemiological studies. Int J Epidemiol 2010;39:469–86. 10.1093/ije/dyp307
    1. Steenhuis TJ, van Aalderen WM, Bloksma N, et al. . Bacille-Calmette-Guerin vaccination and the development of allergic disease in children: a randomized, prospective, single-blind study. Clin Exp Allergy 2008;38:79–85.
    1. Thøstesen LM, Kjaergaard J, Pihl GT, et al. . Neonatal BCG vaccination and atopic dermatitis before 13 months of age: a randomized clinical trial. Allergy 2018;73:498–504. 10.1111/all.13314
    1. Asher MI, Montefort S, Björkstén B, et al. . Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: Isaac phases one and three repeat multicountry cross-sectional surveys. Lancet 2006;368:733–43. 10.1016/S0140-6736(06)69283-0
    1. Mullins RJ. Paediatric food allergy trends in a community‐based specialist allergy practice, 1995–2006. Med J Aust 2007;186:618–21. 10.5694/j.1326-5377.2007.tb01077.x
    1. Sicherer SH, Muñoz-Furlong A, Sampson HA. Prevalence of peanut and tree nut allergy in the United States determined by means of a random digit dial telephone survey. J Allergy Clin Immunol 2003;112:1203–7. 10.1016/S0091-6749(03)02026-8
    1. Gupta R, et al. Increasing hospital admissions for systemic allergic disorders in England: analysis of national admissions data. BMJ 2003;327:1142–3. 10.1136/bmj.327.7424.1142
    1. Downs SH, et al. Continued increase in the prevalence of asthma and atopy. Arch Dis Child 2001;84:20–3. 10.1136/adc.84.1.20
    1. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989;299:1259–60. 10.1136/bmj.299.6710.1259
    1. Netea MG, Quintin J, van der Meer JWM. Trained immunity: a memory for innate host defense. Cell Host Microbe 2011;9:355–61. 10.1016/j.chom.2011.04.006
    1. Novakovic B, Messina N, Curtis N. Chapter 6 - The Heterologous Effects of Bacillus Calmette-Guérin (BCG) Vaccine and Trained Innate Immunity : Faustman DL, The value of BCG and TNF in autoimmunity. 2nd edn Academic Press, 2018: 71–90.
    1. Marchant A, Goetghebuer T, Ota MO, et al. . Newborns develop a Th1-type immune response to Mycobacterium bovis Bacillus Calmette-Guérin vaccination. J Immunol 1999;163:2249–55.
    1. Kleinnijenhuis J, Quintin J, Preijers F, et al. . Long-Lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. J Innate Immun 2014;6:152–8. 10.1159/000355628
    1. Messina NL, Zimmermann P, Curtis N. The impact of vaccines on heterologous adaptive immunity. Clin Microbiol Infect 2019. doi:10.1016/j.cmi.2019.02.016. [Epub ahead of print: 20 Feb 2019].
    1. de Castro MJ, Pardo-Seco J, Martinón-Torres F. Nonspecific (heterologous) protection of neonatal BCG vaccination against hospitalization due to respiratory infection and sepsis. Clin Infect Dis 2015;60:1611–9. 10.1093/cid/civ144
    1. Hollm-Delgado M-G, Stuart EA, Black RE. Acute Lower Respiratory Infection Among Bacille Calmette-Guérin (BCG)–Vaccinated Children. Pediatrics 2014;133:e73–81. 10.1542/peds.2013-2218
    1. Aaby P, Mogensen SW, Rodrigues A, et al. . Evidence of Increase in Mortality After the Introduction of Diphtheria–Tetanus–Pertussis Vaccine to Children Aged 6–35 Months in Guinea-Bissau: A Time for Reflection? Front Public Health 2018;6 10.3389/fpubh.2018.00079
    1. Aaby P, Ravn H, Benn CS. The who review of the possible nonspecific effects of diphtheria-tetanus-pertussis vaccine. Pediatr Infect Dis J 2016;35:1247–57. 10.1097/INF.0000000000001269
    1. Kjærgaard J, Birk NM, Nissen TN, et al. . Nonspecific effect of BCG vaccination at birth on early childhood infections: a randomized, clinical multicenter trial. Pediatr Res 2016;80:681–5. 10.1038/pr.2016.142
    1. Haahr S, Michelsen SW, Andersson M, et al. . Non-Specific effects of BCG vaccination on morbidity among children in Greenland: a population-based cohort study. Int J Epidemiol 2016;45:2122–30. 10.1093/ije/dyw244
    1. Benn CS, Sørup S. Commentary: BCG has no beneficial non-specific effects on Greenland. An answer to the wrong question? Int J Epidemiol 2016;45:2131–3. 10.1093/ije/dyw299
    1. World Health Organization Global hepatitis report 2017. Geneva: World Health Organization, 2017: 83.
    1. Loh W, Tang MLK. The epidemiology of food allergy in the global context. Int J Environ Res Public Health 2018;15:2043 10.3390/ijerph15092043
    1. Peters RL, Koplin JJ, Gurrin LC, et al. . The prevalence of food allergy and other allergic diseases in early childhood in a population-based study: HealthNuts age 4-year follow-up. J Allergy Clin Immunol 2017;140:145–53. 10.1016/j.jaci.2017.02.019
    1. Prescott SL, Pawankar R, Allen KJ, et al. . A global survey of changing patterns of food allergy burden in children. World Allergy Organ J 2013;6 10.1186/1939-4551-6-21
    1. Martin PE, Koplin JJ, Eckert JK, et al. . The prevalence and socio-demographic risk factors of clinical eczema in infancy: a population-based observational study. Clin Exp Allergy 2013;43:642–51.
    1. Osborne NJ, Koplin JJ, Martin PE, et al. . Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. J Allergy Clin Immunol 2011;127:668–76. 10.1016/j.jaci.2011.01.039
    1. Australian Centre for Asthma Monitoring Asthma in Australia 2011. AIHW asthma series: no 4 cat no ACM 22. Canberra: Australian Institute of Health and Welfare, 2011.
    1. Anon The BCG vaccine: information and recommendations for use in Australia. National tuberculosis Advisory Committee update October 2012. Commun Dis Intell Q Rep 2013;37:E65–72.
    1. Harris PA, Taylor R, Thielke R, et al. . Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81. 10.1016/j.jbi.2008.08.010
    1. Australasian Society of Clinical Immunology and Allergy (ASCIA) SPTWP Skin prick testing for the diagnosis of allergic disease: a manual for practitioners. Sydney: ASCIA, 2016.
    1. Pucci N, Novembre E, Cammarata MG, et al. . Scoring atopic dermatitis in infants and young children: distinctive features of the SCORAD index. Allergy 2005;60:113–6. 10.1111/j.1398-9995.2004.00622.x
    1. Osborne NJ, Koplin JJ, Martin PE, et al. . The HealthNuts population-based study of paediatric food allergy: validity, safety and acceptability. Clin Exp Allergy 2010;40:1516–22. 10.1111/j.1365-2222.2010.03562.x
    1. Kusel MMH, de Klerk NH, Holt PG, et al. . Role of respiratory viruses in acute upper and lower respiratory tract illness in the first year of life. Pediatr Infect Dis J 2006;25:680–6. 10.1097/01.inf.0000226912.88900.a3
    1. Anderson EJ, Webb EL, Mawa PA, et al. . The influence of BCG vaccine strain on mycobacteria-specific and non-specific immune responses in a prospective cohort of infants in Uganda. Vaccine 2012;30:2083–9. 10.1016/j.vaccine.2012.01.053
    1. Birk NM, Nissen TN, Ladekarl M, et al. . The association between Bacillus Calmette-Guérin vaccination (1331 SSI) skin reaction and subsequent scar development in infants. BMC Infect Dis 2017;17 10.1186/s12879-017-2641-0
    1. Frankel H, Byberg S, Bjerregaard-Andersen M, et al. . Different effects of BCG strains – a natural experiment evaluating the impact of the Danish and the Russian BCG strains on morbidity and scar formation in Guinea-Bissau. Vaccine 2016;34:4586–93. 10.1016/j.vaccine.2016.07.022
    1. Funch KM, Thysen SM, Rodrigues A, et al. . Determinants of BCG scarification among children in rural Guinea-Bissau: a prospective cohort study. Hum Vaccin Immunother 2018;14:2434–42. 10.1080/21645515.2017.1421879
    1. Turner L, Shamseer L, Altman DG, et al. . Consolidated standards of reporting trials (consort) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. Cochrane Database Syst Rev 2012;5 10.1002/14651858.MR000030.pub2
    1. World Health Organization BCG vaccine: WHO position paper - February 2018 Weekly epidemiological record. Switzerland: World Health, Organization, 2018: 73–96.
    1. Hendry AJ, Dey A, Beard FH, et al. . Adverse events following immunisation with Bacille Calmette-Guérin vaccination: baseline data to inform monitoring in Australia following introduction of new unregistered BCG vaccine. Commun Dis Intell Q Rep 2016;40:E470–4.
    1. Aaby P, Kollmann TR, Benn CS. Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges. Nat Immunol 2014;15:895–9. 10.1038/ni.2961
    1. Shann F. Bcg vaccination in developing countries. BMJ 2010;340 10.1136/bmj.c809
    1. Williams HC, Burney PG, Hay RJ, et al. . The U.K. Working Party's diagnostic criteria for atopic dermatitis. I. derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 1994;131:383–96. 10.1111/j.1365-2133.1994.tb08530.x
    1. Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol 2004;140:1513–9. 10.1001/archderm.140.12.1513
    1. Mallol J, Crane J, von Mutius E, et al. . The International study of asthma and allergies in childhood (Isaac) phase three: a global synthesis. Allergol Immunopathol 2013;41:73–85. 10.1016/j.aller.2012.03.001
    1. Beasley R. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998;351:1225–32.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren